Phase 1 Lupus Trial, Recruiting NCT07491900 Sponsor: Hinge Bio Condition: Lupus
Back to Lupus

Phase 1 Lupus Trial, Recruiting

NCT07491900
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Systemic Lupus Erythematosus (SLE/Lupus) according to recognised medical guidelines (2019 ACR / 2023 EULAR criteria)
  • Your lupus is currently moderately or highly active, based on standard scoring tools used by your doctor
  • If you have lupus nephritis (lupus affecting the kidneys): a kidney biopsy has confirmed a specific type of active kidney involvement, you have a certain level of protein in your urine, and your kidneys are functioning at least at a minimum level (confirm with trial site)
  • If you are in the general lupus group (not kidney-focused): you have not responded well enough to, or could not tolerate, at least one standard lupus treatment
  • You have a positive blood test result for certain markers associated with lupus (such as ANA or related antibodies)
  • Your blood counts and immune levels (such as white blood cells, B cells, and antibody levels) meet minimum required levels (confirm with trial site for exact values)
  • If you are a woman who could become pregnant: you have a negative pregnancy test and agree to use contraception during the trial
  • You are willing and able to give your informed consent to take part voluntarily

Who may not be able to join:

  • You have received certain immune-targeting treatments (anti-CD19 or anti-CD20 therapies) in the last 6 months
  • Your lupus is currently affecting your brain or nervous system (active CNS lupus)
  • You have significant heart, lung, liver, or other serious uncontrolled health conditions
  • You currently have an active infection or have had a serious infection recently
  • You have active Hepatitis B, Hepatitis C, or HIV infection
  • You have had major surgery within the last 4 weeks
  • You have previously had an organ transplant or stem cell transplant
  • You are currently pregnant or breastfeeding
  • You have received certain blood treatments (IVIg or plasmapheresis) within the last 3 months
  • You have received a live vaccine within the last 30 days
  • Your doctor considers that any other condition makes you unsuitable for this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-415-378-4738

Australian sites

Investigational site, Brisbane,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Hinge Bio
Registry
ClinicalTrials.gov
Start date
23 March 2026
Est. completion
24 October 2027

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Number of participants experiencing treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); Maximum tolerated dose (MTD); Number of participants experiencing dose-limiting toxicities (DLTs); Recommended Phase 2 Dose (RP2D)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov